The challenge of liposome targeting in vivo

George Poste, Richard Kirsh, Thomas Koestler

Research output: Chapter in Book/Report/Conference proceedingChapter

1 Citation (Scopus)

Abstract

The ability to “target” drugs to specific cells within the body has long been one of the most cherished goals in therapeutics. Ever since Ehrlich2 foresaw the usc of “bodies which possessed a particular affinity for a certain organ… as carriers by which to bring therapeutic active groups to the organ in question,” considerable ingenuity has been devoted to the study of this challenging problem 35 When the first reports describing the use of liposomes as drug carriers were published in the early 1970s they attracted considerable interest. This interest stemmed in large part from proposals that liposomes might be “targeted” to specific cell types in vivo by constructing liposomes bearing “cell recognition” molecules that could interact selectively with surface determinants on the desired target cell(s). Fascination with this concept, and its seemingly unlimited applications, was not confined to the scientific literature. Numerous newspaper and magazine articles for the general public, as well as segments for television news and science shows, were prepared, some as recently as late 1982,6 describing how liposomes equipped with molecular “zip codes” could serve as “guided missiles” to target drugs and how this approach was about to “revolutionize” drug therapy and the treatment of many important diseases (the terms cited above in quotation marks appear consistently in such articles and should not be viewed by the reader as representative of the terms used routinely by the authors' in describing liposome-cell interactions).

Original languageEnglish (US)
Title of host publicationLiposome Technology Volume III
Subtitle of host publicationTargeted Drug Delivery and Biological Interaction
PublisherCRC Press
Pages1-28
Number of pages28
ISBN (Electronic)9781351082563
ISBN (Print)0849353181, 9781315895017
DOIs
StatePublished - Jan 1 2018
Externally publishedYes

Fingerprint

Liposomes
Literature
Drug Carriers
Newspapers
Television
Cell Communication
Pharmaceutical Preparations
Therapeutics
Drug Therapy

ASJC Scopus subject areas

  • Medicine(all)
  • Pharmacology, Toxicology and Pharmaceutics(all)

Cite this

Poste, G., Kirsh, R., & Koestler, T. (2018). The challenge of liposome targeting in vivo. In Liposome Technology Volume III: Targeted Drug Delivery and Biological Interaction (pp. 1-28). CRC Press. https://doi.org/10.1201/9781351074117

The challenge of liposome targeting in vivo. / Poste, George; Kirsh, Richard; Koestler, Thomas.

Liposome Technology Volume III: Targeted Drug Delivery and Biological Interaction. CRC Press, 2018. p. 1-28.

Research output: Chapter in Book/Report/Conference proceedingChapter

Poste, G, Kirsh, R & Koestler, T 2018, The challenge of liposome targeting in vivo. in Liposome Technology Volume III: Targeted Drug Delivery and Biological Interaction. CRC Press, pp. 1-28. https://doi.org/10.1201/9781351074117
Poste G, Kirsh R, Koestler T. The challenge of liposome targeting in vivo. In Liposome Technology Volume III: Targeted Drug Delivery and Biological Interaction. CRC Press. 2018. p. 1-28 https://doi.org/10.1201/9781351074117
Poste, George ; Kirsh, Richard ; Koestler, Thomas. / The challenge of liposome targeting in vivo. Liposome Technology Volume III: Targeted Drug Delivery and Biological Interaction. CRC Press, 2018. pp. 1-28
@inbook{dcebd71a45014df786913b8da1030d9a,
title = "The challenge of liposome targeting in vivo",
abstract = "The ability to “target” drugs to specific cells within the body has long been one of the most cherished goals in therapeutics. Ever since Ehrlich2 foresaw the usc of “bodies which possessed a particular affinity for a certain organ… as carriers by which to bring therapeutic active groups to the organ in question,” considerable ingenuity has been devoted to the study of this challenging problem 35 When the first reports describing the use of liposomes as drug carriers were published in the early 1970s they attracted considerable interest. This interest stemmed in large part from proposals that liposomes might be “targeted” to specific cell types in vivo by constructing liposomes bearing “cell recognition” molecules that could interact selectively with surface determinants on the desired target cell(s). Fascination with this concept, and its seemingly unlimited applications, was not confined to the scientific literature. Numerous newspaper and magazine articles for the general public, as well as segments for television news and science shows, were prepared, some as recently as late 1982,6 describing how liposomes equipped with molecular “zip codes” could serve as “guided missiles” to target drugs and how this approach was about to “revolutionize” drug therapy and the treatment of many important diseases (the terms cited above in quotation marks appear consistently in such articles and should not be viewed by the reader as representative of the terms used routinely by the authors' in describing liposome-cell interactions).",
author = "George Poste and Richard Kirsh and Thomas Koestler",
year = "2018",
month = "1",
day = "1",
doi = "10.1201/9781351074117",
language = "English (US)",
isbn = "0849353181",
pages = "1--28",
booktitle = "Liposome Technology Volume III",
publisher = "CRC Press",

}

TY - CHAP

T1 - The challenge of liposome targeting in vivo

AU - Poste, George

AU - Kirsh, Richard

AU - Koestler, Thomas

PY - 2018/1/1

Y1 - 2018/1/1

N2 - The ability to “target” drugs to specific cells within the body has long been one of the most cherished goals in therapeutics. Ever since Ehrlich2 foresaw the usc of “bodies which possessed a particular affinity for a certain organ… as carriers by which to bring therapeutic active groups to the organ in question,” considerable ingenuity has been devoted to the study of this challenging problem 35 When the first reports describing the use of liposomes as drug carriers were published in the early 1970s they attracted considerable interest. This interest stemmed in large part from proposals that liposomes might be “targeted” to specific cell types in vivo by constructing liposomes bearing “cell recognition” molecules that could interact selectively with surface determinants on the desired target cell(s). Fascination with this concept, and its seemingly unlimited applications, was not confined to the scientific literature. Numerous newspaper and magazine articles for the general public, as well as segments for television news and science shows, were prepared, some as recently as late 1982,6 describing how liposomes equipped with molecular “zip codes” could serve as “guided missiles” to target drugs and how this approach was about to “revolutionize” drug therapy and the treatment of many important diseases (the terms cited above in quotation marks appear consistently in such articles and should not be viewed by the reader as representative of the terms used routinely by the authors' in describing liposome-cell interactions).

AB - The ability to “target” drugs to specific cells within the body has long been one of the most cherished goals in therapeutics. Ever since Ehrlich2 foresaw the usc of “bodies which possessed a particular affinity for a certain organ… as carriers by which to bring therapeutic active groups to the organ in question,” considerable ingenuity has been devoted to the study of this challenging problem 35 When the first reports describing the use of liposomes as drug carriers were published in the early 1970s they attracted considerable interest. This interest stemmed in large part from proposals that liposomes might be “targeted” to specific cell types in vivo by constructing liposomes bearing “cell recognition” molecules that could interact selectively with surface determinants on the desired target cell(s). Fascination with this concept, and its seemingly unlimited applications, was not confined to the scientific literature. Numerous newspaper and magazine articles for the general public, as well as segments for television news and science shows, were prepared, some as recently as late 1982,6 describing how liposomes equipped with molecular “zip codes” could serve as “guided missiles” to target drugs and how this approach was about to “revolutionize” drug therapy and the treatment of many important diseases (the terms cited above in quotation marks appear consistently in such articles and should not be viewed by the reader as representative of the terms used routinely by the authors' in describing liposome-cell interactions).

UR - http://www.scopus.com/inward/record.url?scp=85053093423&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85053093423&partnerID=8YFLogxK

U2 - 10.1201/9781351074117

DO - 10.1201/9781351074117

M3 - Chapter

AN - SCOPUS:85053093423

SN - 0849353181

SN - 9781315895017

SP - 1

EP - 28

BT - Liposome Technology Volume III

PB - CRC Press

ER -